The Solution

It is SAT’s mission to provide cost-effective cardiac devices and their deployment systems to address the specific needs of the predominantly young patients of developing countries. Since access to cardiac surgery is limited in these countries, it is crucial that our treatments for heart valve diseases are not reliant on the specialised infrastructure needed to perform open-heart surgery.

Deployment Device

This device is designed to deploy a crimped heart valve without occluding the flow of blood in a beating heart. The product is designed to eliminate the need to rapid pace the heart during deployment of the valve. This product does not require open heart surgery and eliminates the need for a heart-lung machine.



Synthetic Heart Valve

This product is designed to allow cost-effective mass-production. This device is mostly intended for use in very young patients and will help to extend their longevity. It will eliminate the need for continuous anti-coagulation medication.


Fig 2 fin - LQ

Mitral Valve Repair

SAT’s mitral valve repair device is directed at percutaneous reduction of significant, symptomatic MR with or without mitral stenosis. The SAT device allows general surgeons to treat mitral valve disease in the absence of cardiology or cardiac surgery expertise.

Simple, continuous pressure feedback allows the clinician to easily locate the commissures of the valve and the anatomical shape of the device provides firm, non-occlusive anchorage while maintaining perpendicularity. Subsequent fine positioning using pressure feedback allows the clinician to identify the regurgitant zone(s) while repeatable, releasable leaflet capture allows the accomplishment of optimal leaflet apposition.

This approach allows clinicians to evaluate the repair and if necessary, release and repeat the procedure until satisfactory pressure and/or echo feedback is obtained. When the leaflets are correctly captured, the repair is actively engaged and a permanent implant is left connecting the leaflets in a bow-tie manner.

The device does not require extensive imaging capabilities such as transesophageal echocardiography and will provide access to treatment for millions of patients currently deemed untreatable due to the unavailability of specialist cardiac centres.